Daily Cosmetic Research Analysis
Today’s most impactful cosmetic-related research spans rigorous clinical evaluation, mechanistic photoprotection, and safety methodology. A double-blind RCT shows a new HA filler (CUREA) is non-inferior to Juvederm for nasolabial folds. Novel topical salt-inducible kinase inhibitors reduce UV-induced DNA damage in humans, and a curated 251-compound photosafety database strengthens non-animal test selection and validation.
Summary
Today’s most impactful cosmetic-related research spans rigorous clinical evaluation, mechanistic photoprotection, and safety methodology. A double-blind RCT shows a new HA filler (CUREA) is non-inferior to Juvederm for nasolabial folds. Novel topical salt-inducible kinase inhibitors reduce UV-induced DNA damage in humans, and a curated 251-compound photosafety database strengthens non-animal test selection and validation.
Research Themes
- Aesthetic dermatology and fillers
- Photoprotection, DNA repair, and photoaging
- Non-animal photosafety assessment and method validation
Selected Articles
1. Efficacy and Safety of New Hyaluronic Acid Filler for Nasolabial Fold Correction: A Double-Blind, Randomized Trial.
In a 24-week, double-blind, randomized split-face non-inferiority trial (n=74), the new monophasic HA filler CUREA was non-inferior to Juvederm for nasolabial fold correction, significantly improving WSRS scores. Safety and patient satisfaction were comparable, with only mild, transient local reactions.
Impact: Provides high-quality RCT evidence supporting a new HA filler as a viable alternative to a widely used comparator with similar safety and effectiveness over 24 weeks.
Clinical Implications: Clinicians can consider CUREA as an alternative to Juvederm for moderate-to-severe nasolabial folds, expecting similar efficacy, safety, and patient satisfaction over 6 months.
Key Findings
- CUREA improved WSRS from 3.16 ± 0.84 to 2.59 ± 0.87 at 24 weeks (P<0.001).
- Non-inferiority to Juvederm was demonstrated in a double-blind, randomized, split-face design.
- Safety and satisfaction were similar to Juvederm with only mild, transient local reactions.
Methodological Strengths
- Double-blind, randomized, split-face non-inferiority design
- Use of validated WSRS and predefined endpoints over 24 weeks
Limitations
- Single-center study with 24-week follow-up may limit generalizability and long-term conclusions
- Non-inferiority margin details beyond summary not provided in abstract
Future Directions: Conduct multicenter, longer-term RCTs including durability beyond 6–12 months, volumetric outcomes, and comparative cost-effectiveness across diverse skin types.
BACKGROUND: Nasolabial folds (NLFs) are a common cosmetic concern that makes people look older. Hyaluronic acid (HA)-based fillers are increasingly popular for minimally invasive facial wrinkle and fold correction. This study aimed to evaluate the efficacy and safety of a new monophasic HA filler, CUREA®, for NLF correction compared to the widely used Juvederm®. METHODS: A 24-week, prospective, single-center, double-blind, randomized, split-face, non-inferiority controlled trial was conducted. Seventy-four participants with moderate-to-severe NLFs were enrolled and treated with CUREA® on one side of the face or Juvederm® on the other. Evaluation included NLF improvement as determined using the Wrinkle Severity Rating Scale (WSRS), participant satisfaction, and adverse events. RESULTS: At 24 weeks, CUREA® significantly improved WSRS scores from 3.16 ± 0.84 at baseline to 2.59 ± 0.87 at week 24 (P <0.001). CUREA® demonstrated efficacy for NLF correction within the predefined non-inferiority margin compared to Juvederm®. The safety profiles and participant satisfaction for CUREA® were similar to those for Juvederm®. Only mild, transient local reactions were observed, and participants were satisfied with the clinical improvement of both fillers throughout the 24-week follow up. CONCLUSIONS: CUREA® is comparable to Juvederm® in NLF correction and safety profiles, and its efficacy lasts up to 24 weeks.
2. A novel approach to target skin photodamage: Topical application of salt inducible kinase inhibitors.
Biochemical, ex vivo, and human clinical data show that topical SIK inhibitors (SLT-008, SLT-001) reduce UV-B–induced CPDs, suppress MMP-1, and lessen erythema, indicating improved DNA repair and anti-photoaging effects. Safety profiles were favorable across assays and clinical testing.
Impact: Introduces a mechanistically novel, clinically translated approach to photodamage mitigation by targeting SIK to enhance DNA repair and reduce matrix degradation.
Clinical Implications: Suggests a post-UV topical adjunct that may enhance DNA repair and reduce photoaging biomarkers, potentially complementing sunscreens, especially for high-risk or UV-exposed individuals.
Key Findings
- Topical SIK inhibitors significantly reduced UV-B–induced CPDs in ex vivo human skin.
- Both agents suppressed MMP-1 expression, a key mediator of collagen breakdown.
- In healthy volunteers, SLT-001 enhanced DNA repair and reduced erythema after UV exposure.
- Safety was supported by in vitro and clinical assessments.
Methodological Strengths
- Multi-tier evidence integrating biochemical assays, ex vivo skin, and human clinical data
- Use of objective biomarkers (CPDs, MMP-1, erythema) aligned with photodamage mechanisms
Limitations
- Sample size and detailed clinical design parameters are not specified in the abstract
- Short-term assessments; durability and real-world effectiveness versus sunscreens remain to be established
Future Directions: Randomized controlled trials comparing SIK inhibitors versus/with sunscreens, dose–response, skin type stratification, and long-term safety/efficacy.
BACKGROUND: Ultraviolet (UV) radiation accelerates skin damage and photoageing, leading to visible signs such as wrinkles, loss of elasticity and uneven pigmentation. UV radiation causes direct DNA damage, primarily through the formation of cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts (6-4PPs), which can lead to mutations and cellular dysfunction if not repaired. While natural defence mechanisms like melanin production and DNA repair pathways mitigate this damage, prolonged or excessive UV exposure can overwhelm these defences, resulting in cumulative skin damage. The melanocortin 1 receptor (MC1R) plays a key role in melanogenesis and also appears to play a role in DNA repair. Salt-inducible kinases (SIKs), critical enzymes in the MC1R pathway, are known to influence melanin production, but their role in DNA repair and photodamage remains unclear. OBJECTIVE: This study investigated the role of SIK in DNA repair and photodamage, focusing on two novel cosmetic ingredients, SIK inhibitors, coded SLT-008 and SLT-001. METHODS: The inhibitory effects of the ingredients on SIK activity were measured using biochemical and cellular assays. Their safety profiles were evaluated through in vitro studies and clinical trials. To analyse their impact on UV-B-induced DNA damage and repair, both inhibitors were topically applied to skin extracts in an ex vivo model. Finally, clinical studies were conducted in healthy volunteers irradiated with UV-R. Efficacy was determined by measuring CPD levels, matrix metalloproteinase-1 (MMP-1), expression and erythema formation following UV exposure. RESULTS: Both ingredients effectively inhibited SIK activity and demonstrated good safety profiles. Ex vivo experiments revealed that immediate post-UV-B application of both ingredients significantly reduced UV-B-induced DNA damage, as shown by decreased CPDs, and promoted tissue repair. Additionally, both inhibitors suppressed MMP-1 expression, an enzyme that plays a key role in the breakdown of collagen, thereby accelerating photoageing. These findings were confirmed in the clinical study, which demonstrated that topically applied SLT-001 enhanced DNA repair, reduced MMP-1 expression and decreased erythema formation. CONCLUSION: Here we described the comprehensive role of SIK inhibition in DNA and dermal repair. This highlights its crucial role in protecting skin against UV-induced photodamage and offering broad protection against actinic ageing. CONTEXTE: les rayons ultraviolets (UV) accélèrent les dommages cutanés et le photovieillissement, entraînant des signes visibles tels que les rides, une perte d’élasticité et une pigmentation inégale. Les rayons UV provoquent des dommages directs de l’ADN, principalement par le biais de la formation de dimères cyclobutyliques de pyrimidine (DCP) et de 6‐4 photoproduits (6‐4PP), ce qui peut entraîner des mutations et un dysfonctionnement cellulaire si celles‐ci ne sont pas réparées. Alors que les mécanismes de défense naturels tels que la production de mélanine et les voies de réparation de l’ADN atténuent ces dommages, une exposition prolongée ou excessive aux UV peut contrebalancer ces défenses, menant à des dommages cutanés cumulés. Le récepteur de la mélanocortine 1 (MC1R) joue un rôle clé dans la mélanogenèse et semble également jouer un rôle dans la réparation de l’ADN. Les kinases inductibles par le sel (Salt‐inducible kinases, SIK), des enzymes essentielles de la voie MC1R, sont connues pour influencer la production de mélanine, mais leur rôle dans la réparation de l’ADN et les photolésions reste incertain. OBJECTIF: cette étude a examiné le rôle des SIK dans la réparation de l’ADN et les photolésions, en se concentrant sur deux nouveaux ingrédients cosmétiques, les inhibiteurs de SIK, SLT‐008 codé et SLT‐001. MÉTHODES: les effets inhibiteurs des ingrédients sur l’activité SIK ont été mesurés à l’aide de dosages biochimiques et cellulaires. Leurs profils de sécurité d’emploi ont été évalués par le biais d’études in vitro et d’essais cliniques. Pour analyser leur impact sur les dommages de l’ADN induits par les UV‐B et la réparation, les deux inhibiteurs ont été appliqués par voie topique sur des extraits cutanés dans un modèle ex vivo. Enfin, des études cliniques ont été menées chez des volontaires en bonne santé irradiés par des UV‐R. L’efficacité a été déterminée en mesurant les taux de DCP, l’expression de la métalloprotéinase matricielle‐1 (MMP‐1), et la formation d’érythème suivant l’exposition aux UV. RÉSULTATS: les deux ingrédients ont inhibé de manière efficace l’activité SIK et démontré de bons profils de sécurité d’emploi. Des expériences ex vivo ont révélé que l’application immédiate post‐exposition aux UV‐B des deux ingrédients réduisait significativement les dommages de l’ADN induits par les UV‐B, tel que démontré par une diminution des DCP, et ont favorisé la réparation tissulaire. En outre, les deux inhibiteurs ont inhibé l’expression de la MMP‐1, une enzyme qui joue un rôle essentiel dans la dégradation du collagène, accélérant ainsi le photovieillissement. Ces résultats ont été confirmés dans l’étude clinique, qui a démontré que la SLT‐001 appliquée par voie topique améliorait la réparation de l’ADN, réduisait l’expression de la MMP‐1 et diminuait la formation d’érythèmes. CONCLUSION: nous décrivons ici le rôle complet de l’inhibition des SIK dans la réparation dermique et de l’ADN. Cela souligne son rôle crucial dans la protection de la peau contre les photolésions induites par les UV et dans l’apport d’une protection étendue contre le vieillissement actinique.
3. PhotoChem Reference Chemical Database for the Development of New Alternative Photosafety Test Methods.
A curated 251-compound PhotoChem database quantified the predictive performance of OECD in vitro photosafety tests against human and animal data, with TG 498 showing the most balanced sensitivity and specificity. Trends in regulatory submissions highlight increasing global adoption of in vitro assays, supporting human-relevant non-animal strategies.
Impact: Provides a rigorously curated reference and head-to-head performance data that can optimize selection of validated non-animal photosafety methods across cosmetics and drugs.
Clinical Implications: Improved test selection can reduce reliance on animal studies, streamline safety assessments for topical agents and sunscreens, and enhance human relevance of photosafety evaluations.
Key Findings
- PhotoChem database curated 251 compounds with in vitro, in vivo, and human photosafety data.
- Against human data, test accuracy was TG 432: 94.2% (49/52), TG 495: 100% (27/27), TG 498: 86.7% (26/30).
- Against animal data, sensitivity remained ≥92.0% for all, with TG 498 showing highest specificity (90.5%).
- Regulatory trend analysis (106 approvals) showed increased in vitro assay use, especially post-2021 MFDS revision.
Methodological Strengths
- Large, curated cross-modal dataset integrating human, animal, and in vitro outcomes
- Direct performance benchmarking of OECD TG 432, 495, and 498 against human/animal reference data
Limitations
- Not a PRISMA meta-analysis; potential selection/publication bias in curated sources
- Database conclusions depend on available human/animal comparators and may not capture all edge cases
Future Directions: Expand compound coverage, include quantitative dose–response harmonization, and prospectively validate integrated testing strategies (ITS) combining TG methods.
Photosafety assessments are a key requirement for the safe development of pharmaceuticals, cosmetics, and agrochemicals. Although in vitro methods are widely used for phototoxicity and photoallergy testing, their limited applicability and predictive power often necessitate supplemental in vivo studies. To address this, we developed the PhotoChem Reference Chemical Database, comprising 251 reference compounds with curated data from in vitro, in vivo, and human studies. Using this database, we evaluated the predictive capacity of three OECD in vitro test guidelines-TG 432 (3T3 NRU), TG 495 (ROS assay), and TG 498 (reconstructed human epidermis)-by comparing the results against human and animal data. Against human reference data, all three test methods showed high sensitivity (≥82.6%) and strong overall accuracy: TG 432 (accuracy: 94.2% (49/52)), TG 495 (100% (27/27)), and TG 498 (86.7% (26/30)). In comparison with animal data, sensitivity remained high for all tests (≥92.0%), while specificity varied: TG 432 (54.3% (19/35)), TG 495 (63.6% (7/11)), and TG 498 (90.5% (19/21)). TG 498 demonstrated the most balanced performance in both sensitivity and specificity across datasets. We also analyzed 106 drug approvals from major regulatory agencies to assess real-world application of photosafety testing. Since the mid-2000s, the use of in vitro phototoxicity assays has steadily increased in Korea, particularly following the 2021 revision of the MFDS regulations. Test method preferences varied by region, with 3T3 NRU and ROS assays most widely used to evaluate phototoxicity, while photo-LLNA and guinea pig tests were frequently employed for photoallergy assay. Collectively, this study provides a valuable reference for optimizing test method selection and supports the broader adoption of validated, human-relevant non-animal photosafety assessment strategies.